T. Rowe Price Investment Management, Inc.

Position in PRME — Prime Medicine, Inc.

CIK 1897612 BALTIMORE, MD

Position in PRME

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$19,325,755

+$248,768 QoQ

Shares Held

5,237,332

-4.5% QoQ

Ownership

2.89%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

of 186 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. PRME ranks #41 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$19,325,755	5,237,332	-4.5%	Shares	Sole	2026-08-14
2026-03-31	$19,076,987	5,481,893	+400.9%	Shares	Sole	2026-05-15
2025-12-31	$3,797,276	1,094,316	-88.1%	Shares	Sole	2026-02-17
2025-09-30	$51,062,717	9,217,097	+42.1%	Shares	Sole	2025-11-14
2025-06-30	$16,017,423	6,484,787	+56.5%	Shares	Sole	2025-08-14
2025-03-31	$8,244,761	4,143,096	+4.2%	Shares	Sole	2025-05-14
2024-12-31	$11,615,257	3,977,828	+4.5%	Shares	Sole	2025-02-14
2024-09-30	$14,734,200	3,807,287	+2.2%	Shares	Sole	2024-11-14
2024-06-30	$19,150,236	3,725,727	+20.6%	Shares	Sole	2024-08-14
2024-03-31	$21,630,581	3,090,083	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.